Stay updated on Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedUpdated site revision from v3.4.2 to v3.4.3. No visible changes to the study details page.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedUpdated the site revision from v3.4.1 to v3.4.2; no user-facing content or functionality appears to be affected.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, which appears to be a minor backend/system update with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedGlossary visibility controls were added (Show glossary, Hide glossary) and footer metadata was updated to Last Update Submitted that Met QC Criteria, No FEAR Act Data, and Revision: v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4 in the page footer.SummaryDifference0.1%

- Check92 days agoChange DetectedFooter now displays Revision: v3.3.3; the HHS Vulnerability Disclosure link and the previous Revision: v3.3.2 reference were removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-TACE in Liver Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-TACE in Liver Cancer Clinical Trial page.